The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Carbamazepine Dosing
Open accessAbstract
Human leukocyte antigen B (HLA-B) is a gene that encodes a cell surface protein involved in presenting antigens to the immune system. The variant allele HLA-B*15:02 is associated with an increased risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in response to carbamazepine treatment. We summarize evidence from the published literature supporting this association and provide recommendations for the use of carbamazepine based on HLA-B genotype (also available on PharmGKB: http://www.pharmgkb.org). The purpose of this article is to provide information to allow the interpretation of clinical HLA-B*15:02 genotype tests so that the results can be used to guide the use of carbamazepine. The guideline provides recommendations for the use of carbamazepine when HLA-B*15:02 genotype results are available. Detailed guidelines regarding the selection of alternative therapies, the use of phenotypic tests, when to conduct genotype testing, and cost-effectiveness analyses are beyond the scope of this document. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines are published and updated periodically on the PharmGKB website at (http://www.pharmgkb.org).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
HLA-B*5701 Screening for Hypersensitivity to Abacavir
Mallal, S., Phillips, E., Carosi, G., Molina, J.-M., Workman, C., Tomažič, J., Jägel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706135 · Cited by 1,835
A marker for Stevens–Johnson syndrome
Chung, W.-H., Hung, S.-I., Hong, H.-S., Hsih, M.-S., Yang, L.-C., Ho, H.-C., Wu, J.-Y., & Chen, Y.-T. (2004) · Nature · doi:10.1038/428486a · Cited by 1,753
Severe Adverse Cutaneous Reactions to Drugs
Roujeau, J. C., & Stern, R. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311906 · Cited by 1,571
Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis
Roujeau, J.-C., Kelly, J. P., Naldi, L., Rzany, B., Stern, R. S., Anderson, T., Auquier, A., Bastuji-Garin, S., Correia, O., Locati, F., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332404 · Cited by 1,465
Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
Hung, S.-I., Chung, W.-H., Liou, L.-B., Chu, C.-C., Lin, M., Huang, H.-P., Lin, Y.-L., Lan, J.-L., Yang, L.-C., Hong, H.-S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409500102 · Cited by 1,284
A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1
Fellay, J., Shianna, K. V., Ge, D., Colombo, S., Ledergerber, B., Weale, M., Zhang, K., Gumbs, C., Castagna, A., Cossarizza, A., et al. (2007) · Science · doi:10.1126/science.1143767 · Cited by 1,235
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Pharmacogenetics: From Bench to Byte— An Update of Guidelines
Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A. H., Mulder, H., Rongen, G. A. P. J. M., van Schaik, R. H. N., Schalekamp, T., Touw, D. J., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.34 · Cited by 1,018
Cited by
Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers
Dunnenberger, H. M., Crews, K. R., Hoffman, J. M., Caudle, K. E., Broeckel, U., Howard, S. C., Hunkler, R. J., Klein, T. E., Evans, W. E., & Relling, M. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124835 · Cited by 511
Self-citationHicks, J. K., Swen, J. J., Thorn, C. F., Sangkuhl, K., Kharasch, E. D., Ellingrod, V. L., Skaar, T. C., Müller, D. J., Gaedigk, A., & Stingl, J. C. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.2 · Cited by 453
Self-citationCaudle, K., Klein, T., Hoffman, J., Muller, D., Whirl-Carrillo, M., Gong, L., McDonagh, E., Sangkuhl, K., Thorn, C., Schwab, M., et al. (2014) · Current Drug Metabolism · doi:10.2174/1389200215666140130124910 · Cited by 446
Self-citationClinically Actionable Genotypes Among 10,000 Patients With Preemptive Pharmacogenomic Testing
Van Driest, S., Shi, Y., Bowton, E., Schildcrout, J., Peterson, J., Pulley, J., Denny, J., & Roden, D. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.229 · Cited by 334
Phillips, E. J., Sukasem, C., Whirl‐Carrillo, M., Müller, D. J., Dunnenberger, H. M., Chantratita, W., Goldspiel, B., Chen, Y., Carleton, B. C., George, A. L., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1004 · Cited by 328
Self-citationvan der Wouden, C., Cambon‐Thomsen, A., Cecchin, E., Cheung, K., Dávila‐Fajardo, C., Deneer, V., Dolžan, V, Ingelman‐Sundberg, M., Jönsson, S., Karlsson, M., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.602 · Cited by 306
Self-citationMeyer, U. A., Zanger, U. M., & Schwab, M. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100502 · Cited by 157
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2
McDonagh, E. M., Boukouvala, S., Aklillu, E., Hein, D. W., Altman, R. B., & Klein, T. E. (2014) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000062 · Cited by 146
Implementation and utilization of genetic testing in personalized medicine
Scott, S., Abul-Husn, N., Owusu Obeng, A., Sanderson, S., & Gottesman, O. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s48887 · Cited by 106
McInnes, G., Sharo, A. G., Koleske, M. L., Brown, J. E. H., Norstad, M., Adhikari, A. N., Wang, S., Brenner, S. E., Halpern, J., Koenig, B. A., et al. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.03.003 · Cited by 86
Metadata
- Authors
- Leckband, S. G., Kelsoe, J. R., Dunnenberger, H. M., George, A. L., Tran, E., Berger, R., Müller, D. J., Whirl-Carrillo, M., Caudle, K. E., & Pirmohamed, M.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2013-05-21
- Volume
- 94
- Issue
- 3
- Pages
- 324-328
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1971946342
- Cited by
- 335
- References
- 58
- FWCI
- 27.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.